Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162292 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT00162292 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants.
The verdict
NCT00162292, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.
Interventions
- DRUG BMS-582949 and Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162292
The ClinicalTrials.gov registry entry for NCT00162292 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-582949 and Methotrexate is the first listed.
NCT00162292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162292 about?
NCT00162292 is a clinical study titled "Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background". The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.
What is the current status of trial NCT00162292?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2005-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00162292?
The interventions under investigation include: BMS-582949 and Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00162292?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.